cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Impel Neuropharma Inc
2 own
7 watching
Current Price
$0
$0.02
(1.73%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
28.96M
52-Week High
52-Week High
10.75
52-Week Low
52-Week Low
0.9275
Average Volume
Average Volume
0.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization28.96M
icon52-Week High10.75
icon52-Week Low0.9275
iconAverage Volume0.01M
iconDividend Yield--
iconP/E Ratio--
What does the Impel Neuropharma Inc do?
Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson s disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Read More
How much money does Impel Neuropharma Inc make?
News & Events about Impel Neuropharma Inc.
Globe Newswire
1month ago
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at...
Globe Newswire
2 months ago
Trudhesa Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel ...
Globe Newswire
2 months ago
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO(rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. ...
Globe Newswire
2 months ago
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023...
Globe Newswire
9 months ago
Trudhesa TRxs Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59%Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market Opportunity Company Reiterated Prescription Guidance Range of 70-85K TRxs for 2022 Initiated Proof-of-Concept ...
Frequently Asked Questions
Frequently Asked Questions
What is Impel Neuropharma Inc share price today?
plus_minus_icon
Can Indians buy Impel Neuropharma Inc shares?
plus_minus_icon
How can I buy Impel Neuropharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Impel Neuropharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Impel Neuropharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Impel Neuropharma Inc?
plus_minus_icon
What is today’s market capitalisation of Impel Neuropharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Impel Neuropharma Inc?
plus_minus_icon
What percentage is Impel Neuropharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Impel Neuropharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.02
(1.73%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00